Curaleaf Sends Aurora an Unsolicited $272 Million Marriage Proposal With a $5 Prenup

After two private letters and a disagreement over who ignored whom, Curaleaf took its offer directly to Aurora shareholders. Corporate cannabis has entered its hostile-wedding era.

NEW YORK, NY. Curaleaf Holdings has announced its intention to launch an unsolicited takeover bid for Aurora Cannabis, a transaction valued at roughly $272 million and structured with the romance of a merger agreement left beneath a windshield wiper.

The intended offer values Aurora at US$4 per share. For every Aurora share, investors would receive 0.3463 of a Curaleaf subordinate voting share plus 75 cents in cash. The proposal represents a 45 percent premium to Aurora's 30-day volume-weighted average price of $2.75, according to Curaleaf, with the value of consideration capped at $5 per Aurora share.

No formal bid had commenced as of the announcement, and there is no assurance one will. This is technically the corporate equivalent of standing outside an ex's house with a ring, a term sheet, and a press release explaining that the wedding remains subject to customary conditions.

Aurora says it did not ghost Curaleaf. Curaleaf says further delay is unjustified. Shareholders have been told to take no action while both companies calmly explain, through securities filings and international media distribution, which one is being weird.

The Courtship Had Two Letters and No Dinner

Aurora confirmed receiving proposal letters dated June 23 and July 7. The company says only the July 7 letter contained financial terms, and even that letter did not spell out the proposed mix of cash and shares. Aurora also says its lead independent director corresponded with Curaleaf CEO Boris Jordan as recently as July 24 and did not discourage continued dialogue.

Curaleaf's public version is less tender. Jordan said Aurora declined to engage and that Curaleaf would take the proposal directly to shareholders because the premium was significant, the strategic logic compelling, and delay unjustified.

This is how cannabis executives say, “I saw you read it.”

The Boof Market Desk reconstructed the courtship using only the documents both companies chose to publish. Curaleaf arrives with a bouquet of subordinate voting shares. Aurora looks through the peephole and forms a special committee. Canaccord Genuity and Norton Rose Fulbright appear as chaperones. Nobody opens the door, but everyone releases a statement about the quality of the conversation occurring through it.

Aurora's board advised shareholders to do nothing until a formal offer could be reviewed. That is sensible. It is also the first known cannabis investor strategy based entirely on not touching anything.

The Ring Is 0.3463 of Another Ring

The offer's construction deserves attention because most of the proposed consideration is Curaleaf stock, not cash. Aurora shareholders would not simply sell and leave. They would trade much of their ownership in one cannabis company for partial ownership in a larger cannabis company that believes combining the two will create value.

This is important because cannabis mergers have a distinguished history of using equity to purchase equity, scale to justify more scale, and adjusted EBITDA to explain why cash remains an aspirational feature.

Curaleaf says the $4 value offers a 45 percent premium to Aurora's 30-day VWAP. It also advertises a 110 percent premium when Aurora's cash and cash equivalents are excluded from the calculation. That second number is the financial equivalent of telling someone you paid a huge premium for their house after subtracting the money you found in the basement.

The $5 cap adds another feature. If Curaleaf's share price rises substantially before the offer is taken up, the number of Curaleaf shares issued per Aurora share would be adjusted so total consideration does not exceed $5. Aurora noted that its own stock traded above that cap as recently as December 18, 2025.

In wedding terms, the proposal includes a ring whose diamond can appreciate, but not past the amount specified by the prenup.

Investors responded to the announcement by pushing Aurora shares sharply higher. A takeover premium is one of the cannabis sector's few reliable methods for generating immediate shareholder enthusiasm without selling additional cannabis.

Synergy Enters Wearing a Global Platform Badge

Curaleaf estimates a combined company would produce approximately $1.5 billion in annual revenue, nearly $350 million in adjusted EBITDA, and at least $40 million in annual cost synergies. The combined operation would reach 17 countries, joining Curaleaf's distribution footprint with Aurora's international medical business and EU-GMP cultivation and manufacturing capacity.

There is a real industrial argument here. Aurora has developed a global medical platform and regulated production capabilities that are difficult to replicate. Curaleaf has broader distribution and significant exposure to the United States. European medical markets offer growth that mature North American recreational markets have struggled to provide.

There is also the phrase “cost synergies,” which in corporate cannabis generally means two head offices enter a conference room and only one payroll leaves.

Forty million dollars in annual synergies will not emerge from a ceremonial blending of logos. It would come from overlapping personnel, facilities, vendors, systems, and ambitions being cut or consolidated.

Somewhere inside the investor presentation is a future slide titled Operational Efficiencies. Somewhere underneath that slide is a human being updating a résumé.

The industry will still celebrate the projected adjusted EBITDA because adjusted EBITDA is cannabis's emotional-support income statement. It allows debt, depreciation, taxes, interest, integration costs,

restructuring charges, and the consequences of earlier enthusiasm to wait politely outside while management discusses the strength of the platform.

Aurora Brings Cash to a Wedding About Growth

Aurora is not merely a weak company waiting to be rescued. Its recent quarterly revenue fell 8.9 percent to C$67.6 million, and its shares had declined about 44 percent during the year before the announcement. But the company also points to a strong balance sheet, a recently completed Safari Flower Company acquisition, and a growing international medical footprint.

That balance-sheet cash is not a footnote. Curaleaf's decision to advertise a much larger premium after excluding it reveals why the asset is attractive. The buyer wants the operations, the international access, the manufacturing capacity, and the money already sitting inside the target.

The proposed combination therefore resembles a cannabis industry wedding where one family praises the other family's culture, distribution network, and European connections while quietly confirming the size of the checking account.

Aurora has formed a special committee of independent directors to assess the proposal alongside its strategic alternatives. Curaleaf has gone public before launching the formal bid. The next stage may involve negotiation, rejection, amended terms, defensive maneuvering, or the entire idea dissolving into the sector's permanent cloud of announced intentions.

Shareholders should remember that “intends to launch” is not “launched,” “implied consideration” is not cash received, and “synergy” is not money until the savings exist without destroying the business that was supposed to create them.

Organic Growth Has Stopped Returning Calls

The larger story is not romantic at all. Mature cannabis companies are running out of easy narratives.

Legalization did not create endless margin. Rescheduling did not instantly repair balance sheets. State expansion brought taxes, price compression, litigation, and expensive infrastructure. International medical growth is real but slower and more technical than the old investor decks promised. When organic growth becomes difficult, corporate cannabis reaches for the oldest substitute available: buy another company and call the combined problems scale.

That does not make this proposal irrational. Curaleaf may genuinely be able to extract value from Aurora's international assets, and Aurora shareholders may decide the premium and combined platform are superior to remaining independent. A strategic acquisition can be intelligent even when the industry's language around it is unbearable.

But this particular courtship captures the moment perfectly. One company believes the future requires owning the other. The other says it is busy executing its plan. The buyer takes the discussion public. The target hires advisers. Both use the word “shareholder” as though the shareholders are children listening from the stairs while their parents discuss a move.

At the Boof hostile-wedding chapel, the vows are ready: for richer, for poorer, for adjusted EBITDA, until dilution do us part. The bouquet is made of cost synergies. The getaway vehicle has seventeen international flags and a dashboard light labeled U.S. regulatory tailwinds.

There may never be a ceremony. There is not even a formal offer yet.

But corporate cannabis has already sent the announcement, reserved the venue, and asked shareholders to hold the date while taking absolutely no action.